News & Updates

Treatment with oral baricitinib steadily inhibits radiographic progression of structural joint damage in most patients with rheumatoid arthritis (RA), while achieving clinical improvement in disease activity, through 5 years as compared with initial conventional synthetic disease-modifying antirheumatic drug (csDMARD) or placebo, results of a study have shown.

Patients with psoriatic arthritis (PsA) do not appear to be at increased risk of mortality from all causes, reveals a study. Moreover, the specific proportionate mortality rate (PMR) in this cohort is similar to that of the general population.

Biologic disease-modifying antirheumatic drug (bDMARD) therapy is effective in reducing ankylosing spondylitis (AS) disease activity, reports a study, noting how treatment has persisted for up to 8 years among patients remaining on their first bDMARD, which is longer than on subsequent agents.

Hospitalization is warranted in one in five patients with new-onset systemic lupus erythematosus (SLE) manifest disease presentations, according to a recent study. Of note, diagnosis has been delayed in nearly 20 percent of patients.

In individuals with psoriatic arthritis (PsA) who have inadequate response or intolerance to ≥1 csDMARD*, the monoclonal antibody risankizumab significantly improved manifestations of PsA, according to the 24-week findings of the phase III KEEPsAKE 1 trial.

The risk for hip fracture slightly increases following osteoporosis drug holidays after long-term therapy with risedronate compared with alendronate, a study has found, adding that future research must examine how best to lessen such risk.

Pregnant women with rheumatic disease and COVID-19 show favourable outcomes, but data are limited by the small sample size and methodology, reports a study.

Epstein-Barr virus (EBV) may be the first trigger for the development of multiple sclerosis (MS) in most cases, says an expert.